Innovent Biologics Inc logo

1801 - Innovent Biologics Inc News Story

HK$34.1 0.9  2.6%

Last Trade - 8:08am

Sector
Healthcare
Size
Large Cap
Market Cap £4.20bn
Enterprise Value £3.90bn
Revenue £38.8m
Position in Universe 282nd / 5984

BRIEF-Hutchison China MediTech, Innovent Expand Collaboration On Sintilimab & Surufatinib

Thu 10th October, 2019 9:06am
Oct 10 (Reuters) - Hutchison China MediTech Ltd  HCM.L :
    * INNOVENT AND CHI-MED EXPAND GLOBAL COLLABORATION
    * INNOVENT AND CHI-MED EXPAND GLOBAL COLLABORATION TO
EVALUATE
COMBINATION OF SINTILIMAB AND SURUFATINIB IN SOLID TUMORS
    * EXPANSION TO ALLOW INNOVENT, CO TO EXPLORE POTENTIAL
APPLICATION
OF TYVYT, SURUFATINIB COMBINATION THERAPY IN SOLID TUMORS
    * EXISTING COLLABORATION WITH INNOVENT ON FRUQUINTINIB IS
PROGRESSING WELL
    * CLINICAL STUDIES WITH NEW COMBINATION WILL BE CONDUCTED
BOTH IN
UNITED STATES AND IN CHINA.

Source text for Eikon:  ID:nRSJ4598Pa 
Further company coverage:  HCM.L 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.